+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Staphylococcal Infection Drugs - Global Strategic Business Report

  • PDF Icon

    Report

  • 183 Pages
  • October 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5991225
The global market for Staphylococcal Infection Drugs was estimated at US$6.0 Billion in 2023, and is projected to reach US$6.8 Billion by 2030, growing at a CAGR of 1.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the market for staphylococcal infection drugs is driven by several factors, including the increasing incidence of drug-resistant staph infections, heightened awareness and surveillance of hospital-acquired infections, and stronger regulatory incentives for developing antibacterial agents. Ongoing research and investment are focused on identifying novel bacterial targets and enhancing the pharmacological properties of existing antibiotics. Meanwhile, global health organizations and governmental bodies are bolstering the market through funding and fast-track approval processes for new drugs, addressing the urgent need for effective staphylococcal infection treatments.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Beta-Lactams Drugs segment, which is expected to reach US$2.2 Billion by 2030 with a CAGR of a 2.6%. The Peptides Drugs segment is also set to grow at 1.8% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $1.6 Billion in 2023, and China, forecasted to grow at an impressive 3.5% CAGR to reach $1.3 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Staphylococcal Infection Drugs Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Staphylococcal Infection Drugs Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Staphylococcal Infection Drugs Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AbVacc, Inc., Acurx Pharmaceuticals, Aptorum Group, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 86 Featured):

  • AbVacc, Inc.
  • Acurx Pharmaceuticals
  • Aptorum Group
  • Armata Pharmaceuticals
  • Basilea Pharmaceutica Ltd.
  • BioVersys
  • Debiopharm Group
  • Destiny Pharma
  • Locus Biosciences, Inc.
  • Lytix Biopharma AS
  • Mabwell Biotech
  • TechnoPhage SA
  • Trellis Bioscience
  • Venus Remedies
  • Xellia Pharmaceuticals;

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Staphylococcal Infection Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rise of Antibiotic Resistance in Staphylococcal Infections
  • Development of Novel Antibacterial Agents
  • Advances in Rapid Bacterial Testing Technologies
  • Increased Incidence of Hospital-Acquired Infections
  • Growing Demand for Effective MRSA Infections Treatment
  • Impact of Global Health Initiatives on Antibiotic Development
  • Advances in Genomics and Pathogen Tracking
  • Public Awareness Campaigns and Education
  • Funding Increases for Antimicrobial Resistance Research
  • Adoption of Combination Therapy Strategies
  • Innovations in Vaccine Development for Staphylococcus Prevention
  • Economic Impact of Staph Infections on Healthcare Systems
  • Shift Towards Personalized Medicine and Tailored Therapies
  • Global Spread of Community-Acquired Staphylococcal Infections
  • Strategic Alliances Among Biopharma and Research Institutes
  • Patient-Centric Approaches in Drug Development
  • Challenges in Treating Multi-Drug Resistant Bacterial Strains
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Staphylococcal Infection Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Staphylococcal Infection Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Beta-Lactams Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Beta-Lactams Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Beta-Lactams Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Peptides Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Peptides Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Peptides Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Quinolones Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Quinolones Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Quinolones Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Macrolides Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Macrolides Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Macrolides Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 21: USA Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: USA 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
CANADA
  • Table 23: Canada Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 24: Canada Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: Canada 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
JAPAN
  • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 26: Japan Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: Japan Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: Japan 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
CHINA
  • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 29: China Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: China Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: China 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
EUROPE
  • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 32: Europe Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 33: Europe Historic Review for Staphylococcal Infection Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: Europe 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 35: Europe Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: Europe Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: Europe 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
FRANCE
  • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 38: France Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: France Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: France 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
GERMANY
  • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 41: Germany Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: Germany Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: Germany 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
ITALY
  • Table 44: Italy Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Italy Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Italy 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 47: UK Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: UK Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: UK 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
SPAIN
  • Table 50: Spain Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: Spain Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: Spain 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
RUSSIA
  • Table 53: Russia Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: Russia Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: Russia 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 56: Rest of Europe Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: Rest of Europe Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Rest of Europe 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 60: Asia-Pacific Historic Review for Staphylococcal Infection Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: Asia-Pacific 16-Year Perspective for Staphylococcal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: Asia-Pacific Historic Review for Staphylococcal Infection Drugs by Drug Class - Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 64: Asia-Pacific 16-Year Perspective for Staphylococcal Infection Drugs by Drug Class - Percentage Breakdown of Value Sales for Beta-Lactams Drugs, Peptides Drugs, Quinolones Drugs, Macrolides Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
AUSTRALIA
  • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Staphylococcal Infection Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbVacc, Inc.
  • Acurx Pharmaceuticals
  • Aptorum Group
  • Armata Pharmaceuticals
  • Basilea Pharmaceutica Ltd.
  • BioVersys
  • Debiopharm Group
  • Destiny Pharma
  • Locus Biosciences, Inc.
  • Lytix Biopharma AS
  • Mabwell Biotech
  • TechnoPhage SA
  • Trellis Bioscience
  • Venus Remedies
  • Xellia Pharmaceuticals;

Table Information